Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Giusti

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
The Lancet. Oncology|June 6, 2022
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J Pinato, Juan Aguilar-Company, Daniela Ferrante, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
The Lancet. Oncology|June 6, 2022
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J Pinato, Juan Aguilar-Company, Daniela Ferrante, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 14